Arix Bioscience plc Correction: Result of AGM

 
TIDMARIX 
 
Arix Bioscience plc 
 
                 Correction: Results of Annual General Meeting 
 
With correction to Table of Resolutions - Numbers 02 and 03. 
 
LONDON, 03 June 2019: Arix Bioscience plc ("Arix", LSE: ARIX) a global venture 
capital company focused on investing and building breakthrough biotech 
companies, announces that its Annual General Meeting (the "Meeting") was held 
on Monday, 3 June 2019 at 10.30am (BST). At the Meeting, the ordinary and 
special resolutions set out in the Notice of the Annual General Meeting dated 2 
May 2019 (the "Notice of AGM"), were proposed and voted on by way of a poll. 
 
Full details of the poll results are set out below and will also be available 
on the Company's website www.arixbioscience.com. 
 
No  RESOLUTION  VOTES FOR    %      VOTES      %     TOTAL     % of    VOTES 
                                   AGAINST           VOTES     ISC   WITHHELD 
                                                              VOTED 
 
01  To receive  79,740,015 100.00     0      0.00  79,740,015 58.86%   3,894 
       the 
    Directors' 
    report and 
   the accounts 
     for the 
   Company for 
     the year 
     ended 31 
     December 
       2018 
 
02  To approve  40,079,954 50.26  39,658,365 49.74 79,738,319 58.86%   5,590 
       the 
    Directors' 
   Remuneration 
      Policy 
 
03  To approve  23,179,050 32.41  48,338,181 67.59 71,517,231 52.79% 8,226,678 
       the 
    Directors' 
   Remuneration 
    Report for 
     the year 
     ended 31 
     December 
       2018 
 
04 To re-elect  75,716,711 94.95  4,025,628  5.05  79,742,339 58.86%   1,570 
     Jonathan 
   Peacock as a 
     Director 
 
05 To re-elect  74,175,937 93.02  5,566,402  6.98  79,742,339 58.86%   1,570 
     Dr Franz 
    Humer as a 
     Director 
 
06 To re-elect  77,691,164 97.43  2,050,547  2.57  79,741,711 58.86%   2,198 
    Professor 
   Trevor Jones 
       as a 
     Director 
 
07 To re-elect  79,739,711 100.00   2,628    0.00  79,742,339 58.86%   1,570 
    Giles Kerr 
       as a 
     Director 
 
08 To re-elect  79,741,711 100.00    628     0.00  79,742,339 58.86%   1,570 
    Dr Joseph 
   Anderson as 
    a Director 
 
09 To re-elect  79,741,711 100.00    628     0.00  79,742,339 58.86%   1,570 
      James 
    Rawlingson 
       as a 
     Director 
 
10 To elect Art 76,266,164 95.64  3,476,175  4.36  79,742,339 58.86%   1,570 
   Pappas as a 
     Director 
 
11   To elect   79,741,711 100.00     0      0.00  79,741,711 58.86%   2,198 
   Mark Breuer 
       as a 
     Director 
 
12      To      72,224,733 90.57  7,524,156  9.43  79,748,889 58.87%   4,020 
    re-appoint 
    PwC LLP as 
   auditors of 
   the Company 
 
13 To authorise 78,313,875 98.21  1,426,485  1.79  79,740,360 58.86%   3,549 
   the Audit & 
       Risk 
   Committee of 
   the Company 
    to fix the 
   remuneration 
      of the 
     auditors 
 
14 To authorise 73,634,398 92.34  6,105,491  7.66  79,739,889 58.86%   4,020 
       the 
   Directors to 
   allot shares 
 
15 To authorise 70,676,320 88.63  9,063,088  11.37 79,739,408 58.86%   4,501 
       the 
   Directors to 
     disapply 
    statutory 
   pre- emption 
    rights in 
    respect of 
    5% of the 
    Company's 
      issued 
      share 
     capital* 
 
16 To authorise 71,033,320 89.08  8,706,088  10.92 79,739,408 58.86%   4,501 
       the 
   Directors to 
     disapply 
    statutory 
   pre- emption 
    rights in 
    respect of 
        an 
    additional 
    5% of the 
    Company's 
   issued share 
     capital* 
 
17 To authorise 79,736,396 99.99    5,063    0.01  79,741,459 58.86%   2,450 
   the Company 
   to buy back 
     shares* 
 
18 To authorise 79,739,242 100.00   2,250    0.00  79,741,492 58.86%   2,417 
       the 
   Directors to 
      call a 
     general 
     meeting 
    other than 
    an annual 
     general 
    meeting on 
     not less 
     than  14 
   clear days' 
     notice* 
 
* Special resolution 
 
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the 
Meeting concerning items other than ordinary business will shortly be available 
for inspection on the National Storage Mechanism, which can be accessed at 
www.hemscott.com/nsm.do 
 
The Board is pleased that all resolutions at the meeting were passed other than 
the resolution to approve last year's Directors' Remuneration Report, 
Resolution 3. Over the next six months we shall engage with those shareholders 
we can identify who did not support this resolution to fully understand their 
concerns. Engagement will also take place with the small number of shareholders 
who did not support the resolution to approve the new Directors' Remuneration 
Policy, which was passed but with a significant minority of votes against. 
 
Since being set up in 2016, the Arix portfolio has grown and developed with 17 
investments to date and four IPOs of portfolio companies in the past year. 
Multiple clinical milestones are expected over the next 12 months and the 
Company looks forward to reporting on continued progress throughout the year. 
 
                                     ENDS 
 
Enquiries 
 
For more information on Arix, please contact: 
 
Arix Bioscience plc 
 
Charlotte Parry, Head of Investor Relations 
 
[phone] 
 
[e-mail] 
 
Optimum Strategic Communications 
 
Mary Clark, Supriya Mathur 
 
T: [phone] 
 
[e-mail] 
 
About Arix Bioscience plc 
 
Arix Bioscience plc is a global venture capital company focused on investing in 
and building breakthrough biotech companies around cutting edge advances in 
life sciences. 
 
We collaborate with exceptional entrepreneurs and provide the capital, 
expertise and global networks to help accelerate their ideas into important new 
treatments for patients. As a listed company, we are able to bring this 
exciting growth phase of our industry to a broader range of investors. 
 
www.arixbioscience.com 
 
 
 
END 
 

(END) Dow Jones Newswires

June 04, 2019 06:59 ET (10:59 GMT)